Merck-AstraZeneca breast cancer drug reduces risk of death by 28% in patients diagnosed early, clinical trial shows
About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.
Tomas Kauer - Moderator 
About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo. Read More
:quality(85):upscale()/2024/12/02/919/n/1922398/2b4b75f6674e20edcc99c3.42112799_.jpg)
